Eye diseases – Web Xpress http://web-xpress.com/ Fri, 20 May 2022 07:46:25 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://web-xpress.com/wp-content/uploads/2021/10/icon-9-150x150.png Eye diseases – Web Xpress http://web-xpress.com/ 32 32 Contrast Kiora Pharmaceuticals (KPRX) and the competition https://web-xpress.com/contrast-kiora-pharmaceuticals-kprx-and-the-competition/ Fri, 20 May 2022 06:10:02 +0000 https://web-xpress.com/contrast-kiora-pharmaceuticals-kprx-and-the-competition/ Kiora Pharmaceuticals (NASDAQ: KPRX – Get a rating) is one of 939 publicly traded companies in the Pharmaceutical Preparations sector, but how does it compare to its competitors? We’ll compare Kiora Pharmaceuticals to similar companies based on earnings strength, dividends, institutional ownership, risk, valuation, profitability, and analyst recommendations. Benefits and evaluation This table compares the […]]]>

Kiora Pharmaceuticals (NASDAQ: KPRXGet a rating) is one of 939 publicly traded companies in the Pharmaceutical Preparations sector, but how does it compare to its competitors? We’ll compare Kiora Pharmaceuticals to similar companies based on earnings strength, dividends, institutional ownership, risk, valuation, profitability, and analyst recommendations.

Benefits and evaluation

This table compares the revenue, earnings per share, and valuation of Kiora Pharmaceuticals and its competitors.

Gross revenue Net revenue Price/earnings ratio
Kiora Pharmaceuticals $10,000.00 -$16.40 million -0.28
Competitors of Kiora Pharmaceuticals $1.86 billion $249.36 million -1.48

Kiora Pharmaceuticals’ competitors have higher revenues and profits than Kiora Pharmaceuticals. Kiora Pharmaceuticals trades at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

29.7% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 45.3% of the shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 58.2% of the shares of Kiora Pharmaceuticals are held by insiders of the company. In comparison, 14.9% of the shares of all “Pharmaceutical Preparations” companies are held by insiders of the company. Strong institutional ownership indicates that large fund managers, hedge funds, and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Kiora Pharmaceuticals has a beta of 0.94, suggesting its stock price is 6% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals’ competitors have a beta of 1.12, suggesting its stock price average is 12% more volatile than the S&P 500. .

Profitability

This table compares the net margins, return on equity and return on assets of Kiora Pharmaceuticals and its competitors.

Net margins Return on equity return on assets
Kiora Pharmaceuticals N / A -131.92% -79.71%
Competitors of Kiora Pharmaceuticals -3,160.46% -1,570.05% -9.52%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Kiora Pharmaceuticals and its competitors, as provided by MarketBeat.com.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Kiora Pharmaceuticals 0 0 2 0 3.00
Competitors of Kiora Pharmaceuticals 6393 21052 43275 870 2.54

Kiora Pharmaceuticals currently has a consensus target price of $2.75, suggesting a potential upside of 550.12%. As a group, the “Pharmaceutical preparations” companies have an upside potential of 134.56%. Given Kiora Pharmaceuticals’ higher consensus rating and higher likely upside potential, equity research analysts clearly believe that Kiora Pharmaceuticals is more favorable than its competitors.

Summary

Kiora Pharmaceuticals beats its competitors on 7 of the 13 factors compared.

About Kiora Pharmaceuticals (Get a rating)

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potentially vision-restoring small molecule, which is in a Phase 1 clinical trial and acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. age. The company is also developing KIO-101, an eye drop in phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for the treatment of non-infectious posterior uveitis; and KIO-201, an eye drop, which is in a Phase 3 clinical trial for the treatment of patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.



Get news and reviews for Kiora Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com’s FREE daily newsletter.

]]>
Surrozen Initiates Assay in Phase 1 Clinical Trial of https://web-xpress.com/surrozen-initiates-assay-in-phase-1-clinical-trial-of/ Wed, 18 May 2022 12:00:00 +0000 https://web-xpress.com/surrozen-initiates-assay-in-phase-1-clinical-trial-of/ SZN-1326 is an Fzd5 Targeted Wnt Mimetic (SWAP) bispecific antibody Beginning of the first part of the three-part Phase 1/1b trial in healthy volunteers SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage company pioneering targeted therapies that selectively activate Wnt tissue repair and […]]]>
  • SZN-1326 is an Fzd5 Targeted Wnt Mimetic (SWAP) bispecific antibody
  • Beginning of the first part of the three-part Phase 1/1b trial in healthy volunteers

SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage company pioneering targeted therapies that selectively activate Wnt tissue repair and regeneration pathway, today announced that the first subject has received a dose in its three-part Phase 1 clinical trial to evaluate SZN-1326 for the potential treatment of moderate to severe ulcerative colitis. The start of the trial is about a quarter earlier than expected. Surrozen also recently announced the publication of an article by Surrozen scientists in the journal Cellular and Molecular Gastroenterology and Hepatology The results highlight the potential of this novel approach for the treatment of inflammatory bowel disease.

The phase 1, randomized, placebo-controlled, single-dose, multiple-escalating-dose study will evaluate the safety, pharmacokinetics, and activity of SZN-1326. The first part of the trial will evaluate single doses of SZN-1326 by intravenous injection or infusion, or subcutaneous injection in healthy volunteers, progressing from 25 mg to 1500 mg. The second part will evaluate multiple escalating doses of SZN-1326 over a four-week period in healthy volunteers, with each subject assigned to one of three dose level cohorts increasing from 75 mg IV to 750 mg IV. The primary endpoint of parts 1 and 2 of the trial is safety and tolerability of SZN-1326 and secondary outcomes include pharmacokinetics as well as anti-drug antibody (ADA) prevalence.

“The dosing of the first participant in our clinical study of SZN-1326 marks an important milestone for Surrozen as we officially transition to a clinical-stage organization,” said Craig Parker, President and CEO of Surrozen. “Furthermore, the assay marks an important step in advancing research into Wnt signaling, which plays a critical role in the regulation of many biological processes. I am proud of our team’s progress in creating uniquely designed antibodies that selectively modulate the Wnt pathway and their robust and rapid execution in completing our preclinical package and launching our clinical development program months earlier than foreseen. We look forward to continuing to build an extensive discovery and clinical pipeline of Wnt antibodies to repair a wide range of tissues and organs damaged by severe disease.

Trudy Vanhove, MD, Ph.D., Chief Medical Officer of Surrozen, added, “This trial is an important step towards bringing a new approach to patients with ulcerative colitis, who still have a significant need for treatments. which have a rapid onset of action, achieve mucosal healing and are non-immunosuppressive. We believe that SZN-1326 holds great promise in this area based on strong results from preclinical studies, including repair of damaged intestinal epithelium, improvement in disease activity, and anti-inflammatory effects. in models of intestinal injury.

SZN-1326 for moderate to severe ulcerative colitis
SZN-1326 is the first candidate in development engineered using Surrozen’s SWAP™ technology and targets the Wnt signaling pathway in the intestinal epithelium. In preclinical animal models of acute and chronic colitis, SZN-1326 has been shown to activate Wnt signaling in the diseased intestine, stimulate intestinal epithelial regeneration, reduce inflammation, and reduce disease activity without adverse effects. treatment-related adverse events observed during 13-week toxicological evaluations in rats and non-human primates (NHP). Surrozen is initially developing SZN-1326 for moderate to severe ulcerative colitis. The phase 1 clinical study is published in the Australian New Zealand Clinical Trial Registry. Click HERE for publication SZN-1326.

About Wnt Signaling
Wnt signaling plays a key role in controlling the development, homeostasis, and regeneration of many essential organs and tissues, including the liver, intestine, lungs, kidneys, retina, central nervous system, cochlea, bones and others. Modulation of Wnt signaling pathways has potential for the treatment of degenerative diseases and tissue damage. Surrozen’s proprietary platform and technologies have the potential to overcome the limitations of pursuing the Wnt pathway as a therapeutic strategy.

About Surrozen
Surrozen is a biotechnology company that discovers and develops drug candidates to selectively modulate the Wnt pathway. Surrozen develops tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application in several disease areas including inflammatory bowel disease, hepatitis, eye disease, hearing loss, pulmonary and respiratory and certain neurological disorders. For more information, visit surrozen.com.

Forward-looking statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements are generally accompanied by words such as “will”, “will”, “plan”, “potential”, “expect”, “advance”, “suggest”, “could” or the negative of these words and similar expressions that predict or indicate future events or trends or are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates SZN-1326, SZN-043 and SZN-413, including anticipated clinical development timelines. , and the potential for using these product candidates to treat human disease. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Surrozen’s management and are not predictions of actual performance. These forward-looking statements are provided for informational purposes only and are not intended to be relied upon and should not be relied upon as a guarantee, assurance, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from the assumptions. Many real events and circumstances are beyond Surrozen’s control. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical or clinical trials regarding SZN-1326, SZN-413, SZN-043, and potential future drug candidates; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to advance SZN-1326, SZN-043, SZN-413 or other future product candidates into and successfully complete preclinical and clinical studies; the effects of the ongoing coronavirus (COVID-19) pandemic or other infectious diseases and natural disasters on Surrozen’s business; volatility in global economic, regulatory and market conditions, which could be adversely affected by the conflict between Russia and Ukraine; and the factors discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 under the heading “Risk Factors” and other documents that Surrozen has filed or will file with the Securities and Exchange Commission. If one of these risks materializes, or if our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen is not currently aware of, or that Surrozen currently believes are not material, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans or forecasts regarding future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its ratings to change. However, while Surrozen may choose to update these forward-looking statements at some time in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be taken to represent Surrozen’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed on forward-looking statements.

Media contacts:
CanaleComm
Ian Stone, Managing Director
Such. : (619) 518-3518
Email: ian.stone@canalecomm.com

Ingrid Mezo, Account Manager
Such. : (301) 473-2881
Email: ingrid.mezo@canalecomm.com

Investor contacts:
Email: Investorinfo@surrozen.com

]]>
Carl Zeiss Meditec (ETR:AFX) PT Fixed at €170.00 by UBS Group https://web-xpress.com/carl-zeiss-meditec-etrafx-pt-fixed-at-e170-00-by-ubs-group/ Mon, 16 May 2022 17:20:08 +0000 https://web-xpress.com/carl-zeiss-meditec-etrafx-pt-fixed-at-e170-00-by-ubs-group/ Carl Zeiss Meditec (ETR: AFX – Get a rating) was given a target price of €170.00 ($178.95) by equity analysts at UBS Group in a research note released on Monday, Borsen Zeitung reports. UBS Group’s price target suggests upside potential of 45.74% from the stock’s previous close. A number of other brokerages have also recently […]]]>

Carl Zeiss Meditec (ETR: AFXGet a rating) was given a target price of €170.00 ($178.95) by equity analysts at UBS Group in a research note released on Monday, Borsen Zeitung reports. UBS Group’s price target suggests upside potential of 45.74% from the stock’s previous close.

A number of other brokerages have also recently commented on AFX. HSBC set a price target of €146.00 ($153.68) on Carl Zeiss Meditec in a Monday, February 14 research report. Hauck and Aufhaeuser set a price target of €215.00 ($226.32) on Carl Zeiss Meditec in a Thursday, April 21 research report. Deutsche Bank Aktiengesellschaft set a €210.00 ($221.05) price target on Carl Zeiss Meditec in a Monday, February 14 research report. Finally, Deutsche Bank Rese… set a price target of €210.00 ($221.05) on Carl Zeiss Meditec in a research report on Monday.

AFX traded at €5.95 ($6.26) in midday trading on Monday, rising to €116.65 ($122.79). The company had a trading volume of 175,654 shares, compared to an average volume of 94,405. The company has a quick ratio of 2.90, a current ratio of 3.58 and a leverage ratio of 7.23. The company has a 50-day moving average of €133.53 and a two-hundred-day moving average of €151.85. The company has a market capitalization of $10.43 billion and a P/E ratio of 45.94. Carl Zeiss Meditec has a 1-year minimum of €104.75 ($110.26) and a 1-year maximum of €202.00 ($212.63).

About Carl Zeiss Meditec (Get a rating)

Carl Zeiss Meditec AG operates as a medical technology company in Germany, the rest of Europe, the USA, Asia and internationally. It operates through two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers products and solutions for the diagnosis and treatment of eye diseases; and systems and consumables for cataract, retina and refractive surgeries.

Read more



Get news and reviews for Carl Zeiss Meditec Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Carl Zeiss Meditec and related companies with MarketBeat.com’s free daily email newsletter.

]]>
Clinical catalysts for biotech stock on track for mid-2022 https://web-xpress.com/clinical-catalysts-for-biotech-stock-on-track-for-mid-2022/ Sun, 15 May 2022 09:20:26 +0000 https://web-xpress.com/clinical-catalysts-for-biotech-stock-on-track-for-mid-2022/ Upcoming potential stock movement events include new data regarding the company’s lead therapeutic candidate for age-related eye disease, according to a report from ROTH Capital Partners. Unity Biotechnology Inc. (UBX:NASDAQ) is approaching three catalysts expected this year related to its ophthalmic clinical programs, ROTH Capital Partners analyst Elmer Piros reported in a May 12 statement. […]]]>

Upcoming potential stock movement events include new data regarding the company’s lead therapeutic candidate for age-related eye disease, according to a report from ROTH Capital Partners.

Unity Biotechnology Inc. (UBX:NASDAQ) is approaching three catalysts expected this year related to its ophthalmic clinical programs, ROTH Capital Partners analyst Elmer Piros reported in a May 12 statement. research note.

Piros relayed upcoming events. One, scheduled for mid-2022, is for 12-week results from UNITY’s ongoing Phase 2a BEHOLD trial of UBX1325 in patients with diabetic macular edema.

The second event is Unity identifying other potential drug candidates, from its Tie2-VEGF bispecific program and Tie2 antibody UBX2050, to pursue through clinical trials.

The third, expected in Q4/22, is the first data set, at 16 weeks, from Unity’s just-initiated Phase 2 ENVISION trial evaluating the biotech’s senolytic agent UBX1325 in patients with age-related neovascular macular degeneration. Patients will be assessed for safety and effectiveness every eight weeks. The primary endpoint is visual acuity.

In ENVISION, 46 treatment-refractory patients will receive injections of 10 micrograms of UNITY’s UBX1325 at weeks zero and four or receive standard treatment, 2 milligrams of aflibercept every eight weeks for up to 24 weeks.

Piros also reported that ROTH had lowered its target price on UNITY to $3 per share from $4 as the biotech is expected to have “declining liquidity” across the board. Now, however, the drug developer has enough cash for about 12 months of operations, with $79 million at the end of Q1/22.

ROTH Capital Partners maintains its buy rating on UNITY Biotechnology.


You want to be the first to know about interesting information Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise’ reports newsletter.

Subscribe

Disclosures

1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own shares in the following companies mentioned in the article: None. She or members of her household are compensated by the following companies mentioned in this article: None.

2) The following companies mentioned in this article are sponsors of the Streetwise Reports billboard: None. Click here for important information on referral fees.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is provided for informational purposes only and does not constitute a recommendation to buy or sell any securities.

4) The article does not constitute investment advice. Each reader is encouraged to consult their financial professional and any action taken by a reader as a result of the information presented here is their own responsibility. By opening this page, each reader accepts and consents to the full Streetwise Reports Terms of Service and Legal Notice. This article is not an investment solicitation. Streetwise Reports does not provide general or specific investment advice and information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the activities, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or their family members, as well as those interviewed for articles and interviews on the site, may take a long or short position in the titles mentioned. Directors, officers, employees or members of their immediate family are prohibited from making purchases and/or sales of such securities on the open market or otherwise from the time of the decision to publish an article until three days working days after the publication of the article. . The foregoing prohibition does not apply to articles which, in substance, merely reproduce previously published company press releases.

6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed healthcare professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures for Roth Capital Partners, UNITY Biotechnology Inc., May 12, 2022

ROTH creates a market in shares of Unity Biotechnology, Inc. and as such buys and sells clients on a principal basis. Shares of Unity Biotechnology, Inc. may be subject to the Securities and Exchange Commission’s Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business dealings with the covered companies mentioned in this report within the next three months. Material, information and facts discussed in this report, other than information about ROTH Capital Partners, LLC and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be relied upon as a comprehensive analysis of the company, industry, or security discussed in the report. Additional information is available upon request. However, this is not an offer or solicitation of the securities in question. Any opinions or estimates contained in this report are subject to change without notice. An investment in the shares may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written permission of ROTH.

]]>
Eye disease biotech OKYO Pharma further cuts deal size by 50% ahead of $3M U.S. IPO https://web-xpress.com/eye-disease-biotech-okyo-pharma-further-cuts-deal-size-by-50-ahead-of-3m-u-s-ipo/ Fri, 13 May 2022 20:32:11 +0000 https://web-xpress.com/eye-disease-biotech-okyo-pharma-further-cuts-deal-size-by-50-ahead-of-3m-u-s-ipo/ OKYO Pharma, a preclinical biotech developing a lipid analogue of chemerin for dry eye disease, on Friday reduced the size of the proposed deal for its upcoming IPO. The St. Peter Port, Guernsey-based company now plans to raise $3m by offering 0.5m ADS at a price of $4.92, the latest converted close of its shares […]]]>

OKYO Pharma, a preclinical biotech developing a lipid analogue of chemerin for dry eye disease, on Friday reduced the size of the proposed deal for its upcoming IPO.

The St. Peter Port, Guernsey-based company now plans to raise $3m by offering 0.5m ADS at a price of $4.92, the latest converted close of its shares on the LSE (OKYO) . The company had recently filed in April to offer 1 million ADS at $5.20, and originally planned to offer 1.9 million ADS at $5.24. Under the revised terms, OKYO Pharma will raise -50% less than expected and achieve a fully diluted market value of $107 million.

Because the company now plans to raise less than $5 million, OKYO Pharma will be excluded from Renaissance Capital’s IPO statistics.

OKYO Pharma develops next-generation therapies for inflammatory eye diseases and eye pain. Its lead candidate is OK-101, a lipid analog of chemerin originally developed for keratoconjunctivitis sicca, or dry eye disease (DED). The company expects to file an IND in 2H22, followed by the start of a phase 2 trial in DED patients in 4Q22. OKYO also plans to evaluate OK-101 in patients with ocular neuropathic pain, uveitis and allergic conjunctivitis.

OKYO Pharma was founded in 2007 and plans to list on Nasdaq under the symbol OKYO. ThinkEquity is the sole bookrunner on the transaction.

]]>
Visus Therapeutics and Zhaoke Ophthalmology Announce Licensing Agreement to Commercialize Presbyopia Treatment Overseas https://web-xpress.com/visus-therapeutics-and-zhaoke-ophthalmology-announce-licensing-agreement-to-commercialize-presbyopia-treatment-overseas/ Wed, 11 May 2022 12:02:14 +0000 https://web-xpress.com/visus-therapeutics-and-zhaoke-ophthalmology-announce-licensing-agreement-to-commercialize-presbyopia-treatment-overseas/ Visus Therapeutics Inc. and Zhaoke Ophthalmology Limited (“ZKO”) today announced an exclusive license agreement for the development and commercialization of BRIMOCHOL PF and Carbachol PF in Greater China, South Korea and certain US territories. South East Asia. According to Visus, BRIMOCHOL PF and Carbachol PF are investigational preservative-free therapeutic products designed to be long-acting, once-daily […]]]>

Visus Therapeutics Inc. and Zhaoke Ophthalmology Limited (“ZKO”) today announced an exclusive license agreement for the development and commercialization of BRIMOCHOL PF and Carbachol PF in Greater China, South Korea and certain US territories. South East Asia.

According to Visus, BRIMOCHOL PF and Carbachol PF are investigational preservative-free therapeutic products designed to be long-acting, once-daily eye drops to correct near vision loss associated with presbyopia.

Under the terms of the agreement, ZKO will be responsible for the clinical development and regulatory approval of BRIMOCHOL PF and Carbachol PF in the specified territories, and then for product commercialization activities. Visus will receive an upfront payment of $15 million and potentially receive up to $115 million in regulatory, marketing and sales-focused stages. In addition, Visus will earn tiered royalties on future sales of these products in the contracted territories. ZKO will leverage the extensive clinical development experience and plans Visus has in place for its enrolling Phase 3 studies to meet required clinical requirements and bring products to market quickly.

ZKO’s clinical development plans include submitting a new drug application to the China Drug Evaluation Center for CsA ophthalmic gel for short-term dry eye, continuing to enroll patients for the study of phase 3 NVK002 for myopia, as well as the launch of the clinical study in China. for presbyopia corresponding to the ongoing Phase 3 study of BRIMOCHOL PF and Carbachol PF in the United States.

Ben Bergo, co-founder and CEO of Visus Therapeutics, noted that the company exists about the opportunity to work with ZKO.

“Our market research indicates that there is strong demand for a long-acting eye drop that corrects presbyopia in China, and we are excited to collaborate with Zhaoke Ophthalmology to accelerate clinical development and launch our lead candidates in Greater China, South Korea and select Southeast Asian markets,” it said in a statement.

“After extensive analysis of other presbyopia-correcting eye drops in development, Zhaoke Ophthalmology is confident that BRIMOCHOL PF and Carbachol PF have the potential to become best-in-class drugs for the treatment of presbyopia, which is supported unparalleled experience in the ophthalmology category,” said Dr. Li Xiaoyi (Benjamin), Chairman of the Board and CEO of Zhaoke Ophthalmology Limited, in the release. “We will become the first ophthalmic pharmaceutical company in China with innovative drugs in advanced clinical development covering the three main fronts of eye diseases, namely dry eye, myopia and presbyopia.We will continue to expand our pipeline of leading ophthalmic actives to the front and back of the eye and to advance these promising experimental therapeutics to market in Chin e and beyond as quickly as possible. »

]]>
North Point Eye Care: complete services for the whole family! https://web-xpress.com/north-point-eye-care-complete-services-for-the-whole-family/ Sat, 07 May 2022 03:58:48 +0000 https://web-xpress.com/north-point-eye-care-complete-services-for-the-whole-family/ Dr. Thuy Le’s enthusiasm for optometry started at an early age in a very unique way. As a child, she was watching television when an advert appeared asking for donations for children with eye disease. That’s when something clicked for the young optometrist. Now she works at North Point Eye Care – an Alpharetta practice […]]]>

Dr. Thuy Le’s enthusiasm for optometry started at an early age in a very unique way. As a child, she was watching television when an advert appeared asking for donations for children with eye disease.

That’s when something clicked for the young optometrist.

Now she works at North Point Eye Care – an Alpharetta practice offering full optometric services, specializing in the correction of eye diseases and injuries as well as Ortho-K solutions for children suffering from eye strain from tablets.

Knowing her empathy for the children she saw in those TV commercials, it’s no wonder she enjoys working especially with children. Myopia management – ​​or a treatment to slow myopia – in young people is one of Dr. Le’s passions.

Ortho-K solutions – often compared to orthodontic appliances, except for the eyes – aim to improve adolescent vision aim to improve adolescent vision through the use of fitted contact lenses. This is a specialty that most practices do not offer.

Another specialty area of ​​North Point Eye Care is the diagnosis and treatment of eye diseases and injuries, with testing and care for cataracts, glaucoma and other common eye conditions.

North Point Eye Care staff provide preoperative and postoperative care for eye diseases as well as prompt response and treatment for eye emergencies such as corneal scratches and foreign body removal.

From treating eye diseases to helping young people improve their vision, much of the practice’s business relies on word of mouth.

That, and hard-to-find designer frames from places like Italy and France. North Point Eye Care offers a wide range of premium eye care products including eyeglasses, specialty eyewear, frames and contact lenses.

And you won’t have to wait long to browse these products. Dr. Le respects and values ​​his patients time – rarely making you wait more than 5 minutes to be seen by staff.

That’s because Dr. Le’s clients – like you – are busy. “Many of my patients are business men or women. Professionals with time-sensitive schedules. I would never make them wait long to see me.

North Point Eye Care patients benefit from a wide range of optometric services and eye care products in a comfortable and friendly environment, aiming to make it a positive experience.

The team of eye care professionals are dedicated to helping all patients understand their benefits, schedule appointments, and fulfill their eye doctor’s orders. Opticians will also guide you in choosing the perfect pair of glasses.

For more information or to make an appointment, visit NorthPointEyeCare.comE-mail specsinthecity2020@gmail.com or call 770-410-1540.

North Point Eye Care

NorthPointEyeCare.com

770-410-1540

specsinthecity2020@gmail.com

5755 North Point Drive, Suite 222

Alpharetta, GA 30022

]]>
IRIDEX Co. (NASDAQ:IRIX) Short Interest Up 18.5% in April https://web-xpress.com/iridex-co-nasdaqirix-short-interest-up-18-5-in-april/ Wed, 04 May 2022 07:01:06 +0000 https://web-xpress.com/iridex-co-nasdaqirix-short-interest-up-18-5-in-april/ IRIDEX Co. (NASDAQ:IRIX – Get a rating) recorded a sharp increase in short-term interest in April. As of April 15, there was short interest totaling 81,300 shares, an 18.5% increase from the March 31 total of 68,600 shares. Approximately 0.6% of the company’s shares are sold short. Based on an average daily volume of 39,800 […]]]>

IRIDEX Co. (NASDAQ:IRIXGet a rating) recorded a sharp increase in short-term interest in April. As of April 15, there was short interest totaling 81,300 shares, an 18.5% increase from the March 31 total of 68,600 shares. Approximately 0.6% of the company’s shares are sold short. Based on an average daily volume of 39,800 shares, the day-to-cover ratio is currently 2.0 days.

Institutional investors have recently bought and sold shares of the company. Morgan Stanley acquired a new stake in IRIDEX during Q1 worth approximately $40,000. Bank of New York Mellon Corp acquired a new stake in IRIDEX during Q3 worth approximately $266,000. Northern Trust Corp increased its equity stake in IRIDEX by 6.4% during the fourth quarter. Northern Trust Corp now owns 38,889 shares of the medical equipment supplier worth $237,000 after buying 2,347 more shares last quarter. State Street Corp increased its stake in IRIDEX shares by 53.5% during the 4th quarter. State Street Corp now owns 40,762 shares of the medical equipment supplier worth $249,000 after buying 14,200 more shares last quarter. Finally, Millennium Management LLC purchased a new stock position in IRIDEX during Q2 for a value of approximately $378,000. 22.10% of the shares are held by institutional investors.

Several research companies have recently published reports on IRIX. Zacks Investment Research upgraded IRIDEX from a “hold” rating to a “sell” rating in a Wednesday, March 16 research report. StockNews.com began covering IRIDEX in a research report on Wednesday, April 27. They set a “buy” rating for the company.

Shares of NASDAQ IRIX opened at $3.77 on Wednesday. IRIDEX has a 52-week low of $3.69 and a 52-week high of $9.46. The company has a 50-day moving average price of $4.33 and a 200-day moving average price of $5.62. The stock has a market capitalization of $59.88 million, a PE ratio of -11.09 and a beta of 1.23.

IRIDEX (NASDAQ:IRIXGet a rating) last released its quarterly earnings data on Thursday, March 10. The medical equipment supplier reported ($0.15) earnings per share for the quarter, missing analyst consensus estimates of ($0.11) by ($0.04). IRIDEX had a negative return on equity of 32.53% and a negative net margin of 9.69%. The company posted revenue of $15.25 million for the quarter, versus analyst estimates of $15.18 million. In the same period a year earlier, the company posted ($0.01) earnings per share. As a group, research analysts expect IRIDEX to post -0.5 EPS for the current year.

IRIDEX company profile (Get a rating)

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic laser systems, delivery devices and consumable instruments to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as the Cyclo G6 laser system for the treatment of glaucoma; the IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and the OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments.

Featured articles



Get news and reviews for IRIDEX Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for IRIDEX and related companies with MarketBeat.com’s FREE daily email newsletter.

]]>
Test to detect rare eye cancer in unborn babies rolled out across NHS https://web-xpress.com/test-to-detect-rare-eye-cancer-in-unborn-babies-rolled-out-across-nhs/ Mon, 02 May 2022 23:01:00 +0000 https://web-xpress.com/test-to-detect-rare-eye-cancer-in-unborn-babies-rolled-out-across-nhs/ A genetic test to detect a rare form of eye cancer in babies in the womb is being rolled out across the NHS for families at risk. The test detects babies with retinoblastoma and is likely to identify around 50 cases each year in England. Retinoblastoma is a rare type of eye cancer that can […]]]>

A genetic test to detect a rare form of eye cancer in babies in the womb is being rolled out across the NHS for families at risk.

The test detects babies with retinoblastoma and is likely to identify around 50 cases each year in England.

Retinoblastoma is a rare type of eye cancer that can affect young children, usually under the age of five.

If detected early, the disease can often be successfully treated and more than nine out of 10 children who have it are cured.

However, if the cancer is not detected, it can lead to the loss of one or both eyes, or even death.

One of the signs of retinoblastoma is an unusual white reflection in the pupil of the eye – this may look like a cat’s eye which reflects light and may be visible in photographs.

The new non-invasive NHS test, developed at Birmingham Women’s and Children’s NHS Foundation Trust, can detect genetic changes that cause retinoblastoma.

A blood sample is taken from the mother before she delivers for the test (PA)

(PA Archive)

It will be offered to pregnant women with a known family history of the disease, often mentioned during pregnancy appointments,

For the test, a blood sample is taken from the mother before birth and tested and analyzed for mutations, which can determine with almost 100% accuracy whether the baby will develop retinoblastoma.

The test looks for a mutation in the RB1 gene. About nine out of ten children born with an RB1 mutation develop retinoblastoma.

Detecting the cancer so early means treatment can begin on the affected eye as soon as the baby is born, with doctors closely monitoring the other eye for any signs.

The test can also predict whether the disease might develop in siblings.

NHS Chief Executive Amanda Pritchard said: “The introduction of this pioneering new test is fantastic news for babies and their parents, and has the potential to save hundreds of lives over the next few years.

“Cancer is such a terrible disease and a baby born with it can have a huge impact on parents and families during what should be an incredibly happy time.

“But, backed by world-class innovation and services like the NHS Genomic Medicine Service, through the long-term plan the NHS is developing and delivering cutting-edge treatments like this to help save lives and keep families together.”



Since the tumors were quite severe when he was born, the fact that he could be treated immediately definitely affected his outcome.

Siani Bainbridge, mother of a newborn with retinoblastoma

Siani Bainbridge, 22, from County Durham, had retinoblastoma as a child and feared her toddler son Oscar might also be a carrier of the faulty gene.

She participated in the test trial and discovered that Oscar had retinoblastoma.

She said: “As the tumors were quite severe when he was born, the fact that he could be treated immediately definitely affected his outcome. It was good to know that the day he was diagnosed, it was ready, it was gone.

Just a week after his birth, Oscar began cancer treatment, which involved chemotherapy and then laser therapy.

While doctors could not save sight in one eye, he did not have his eyeball removed and retained sight in the other eye.

The test is one of more than 15 new tests and amendments added to the National Genomic Test Directory, which defines genomic tests for diseases available through the NHS Genomic Medicine Service.

The directory covers over 3,000 rare diseases and over 200 types of cancer.

]]>
Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome… | News https://web-xpress.com/kala-pharmaceuticals-to-present-clinical-data-for-kpi-012-its-mesenchymal-stem-cell-secretome-news/ Sun, 01 May 2022 13:00:00 +0000 https://web-xpress.com/kala-pharmaceuticals-to-present-clinical-data-for-kpi-012-its-mesenchymal-stem-cell-secretome-news/ — Data demonstrates rapid and complete wound healing, with six out of eight patients (75%) achieving complete healing within four weeks; All remained cured through end of follow-up — — All patients with pain at baseline reported no pain at week 3 — — KPI-012 was well tolerated and no safety issues no significant was […]]]>

— Data demonstrates rapid and complete wound healing, with six out of eight patients (75%) achieving complete healing within four weeks; All remained cured through end of follow-up — — All patients with pain at baseline reported no pain at week 3 — — KPI-012 was well tolerated and no safety issues no significant was observed — — In the process of submitting Investigational New Drug (IND) application and launching the phase 2/3 trial in Q4 2022 —

ARLINGTON, Mass., May 01, 2022 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ: KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for eye diseases , today reported clinical data from a Phase 1b trial of KPI-012, its new acellular secretome therapy for the treatment of serious eye diseases caused by impaired wound healing. As previously described, treatment with KPI-012 was well tolerated and resulted in significant improvements in patients with various etiologies of persistent corneal epithelial defect (PCED), with complete recovery from PCED in six of eight evaluable patients. The data will be presented on Tuesday, May 3 during a poster session at the 2022 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO).

“The clinical activity seen to date with KPI-012 is encouraging,” said Valeria Sánchez-Huerta, MD FACS, Medical Director of Asociación para Evitar la Ceguera en México (Association for the Prevention of Blindness in Mexico ) and investigator in the phase 1b trial. “PCED is an impaired corneal wound healing disease that, if left untreated, can lead to infection, corneal perforation, and irreversible vision loss. Achievement of rapid and complete wound healing, as well as reduction of PCED-related pain and improvement in visual acuity and corneal opacity, in patients with a range of etiologies under underlying is remarkable, especially after such a short duration of treatment. Based on these early data, I believe KPI-012 could become the first treatment to treat PCED across all etiologies and I look forward to further evaluating its potential in future studies.

PCED, which is defined as a persistent corneal abnormality or sore that does not heal and is refractory to conventional treatments, is a rare disease with an estimated incidence in the United States of 100,000 cases per year. PCED can have various etiologies including neurotrophic keratitis, surgical epithelial debridement, microbial/viral keratitis, corneal transplant, limbal stem cell deficiency, and mechanical and chemical trauma and can lead to corneal ulceration, perforation , stromal scarring, secondary infections and significant vision loss.

Healing after corneal injury follows a highly coordinated process involving growth factors, cell signaling, proliferation, migration, and extracellular matrix remodeling. In patients with PCED, there is an imbalance of key biomolecules, including growth factors and cytokines, resulting in significant inflammation, impaired innervation, and disruption of the protective layers of the corneal epithelium and of the stroma. KPI-012 was designed specifically to address this imbalance: it is a novel mesenchymal stem cell (MSC) secretome derived from human bone marrow containing numerous human biomolecules including protease inhibitors, matrix proteins , growth factors and neurotrophic factors, which provide a multifactorial mechanism of action to treat corneal wound healing disorders in many etiologies.

“We are thrilled to present these exciting data from the first KPI-012 clinical trial,” said Kim Brazzell, Ph.D., head of research and development and medical director at Kala Pharmaceuticals. “These data, which served as the basis for our acquisition of Combangio last year, highlight the potential of KPI-012 to offer a new approach to the treatment of PCED, as well as other rare diseases forward. and the back of the eye. Our goal remains to advance KPI-012 into a Phase 2/3 trial for PCED later this year, as we aim to provide new and better options for people living with serious ocular surface diseases.

The poster presentation is now available on the Kala Pharmaceuticals website at https://investors.kalarx.com/presentations.

ARVO Presentation Highlights

The phase 1b, prospective, open-label, single-arm clinical trial enrolled 12 patients, including three in a preliminary safety cohort and nine in an efficacy cohort. Within the efficacy cohort, patients presented with PCED of various etiologies and durations ranging from 15 to 871 days. Patients were treated with KPI-012 twice daily for up to four weeks, with follow-up at two, four and 12 weeks after their last treatment dose. The key efficacy endpoint was complete healing of corneal defects assessed by corneal staining. Other efficacy parameters included reduction in defect size, visual acuity and corneal opacity. Safety measures included tolerance/pain, intraocular pressure and adverse events.

Eight patients were evaluable for efficacy assessment; one participant was ineligible due to an unrelated adverse event. Improvement was seen in seven of eight evaluable patients, with six of eight achieving complete healing by the end of week 4, including four patients who were healed by the end of week 1 and one patient who was healed at the end of week 2 The six cured patients remained cured until the end of the follow-up period. Additionally, improvement in PCED lesion size was observed in the two patients who did not experience complete healing. In the eight patients, the mean improvement in lesion size between the start and end of treatment was -16.23 mm. KPI-012 was well tolerated in the trial.

Clinical development plans

Kala plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) and, subject to regulatory approval, initiate a Phase 2/3 clinical trial of the KPI- 012 in PCED patients in Q4 2022 Kala believes this trial could be the first of two pivotal trials required. The FDA has granted orphan designation KPI-012 for the treatment of PCED and the company believes it may also qualify for fast-track and breakthrough designations.

In addition, Kala believes that KPI-012’s multifactorial mechanism of action also makes it a technology platform and is evaluating KPI-012 for potential extension to rare disease indications of the front of the eye, such as deficiency. in limbal stem cells and Sjögren’s syndrome, as well as certain rare diseases of the back of the eye, such as retinitis pigmentosa and optic neuritis.

About Kala Pharmaceuticals, Inc.

Kala is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for eye diseases. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) drug delivery technology to two eye therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS® (loteprednol etabonate ophthalmic suspension). loteprednol) 1%. The Company also has a pipeline of development programs, including a clinical-stage secretome product candidate, KPI-012, initially targeting persistent corneal epithelial defects (PCEDs) and several preclinical New Chemical Entity (NCE) development programs. ) owners aimed at addressing unmet medical needs, including diseases of the front and back of the eye. For more information about Kala, please visit www.kalarx.com.

Forward-looking statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. Any statements contained in this press release regarding Kala’s future expectations, plans and prospects, including but not limited to statements about Kala’s expectations regarding KPI-012, future development or commercialization of the KPI -012, the conduct and timing of clinical trials, Kala’s plans to advance its pipeline of preclinical development programs aimed at treating diseases in the front and back of the eye, are forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements due to a variety of important factors, including those discussed in the “Risk Factors” section of Kala’s Annual Report on Form 10-K, the most recently filed quarterly report on Form 10-Q and other documents filed by Kala with the Securities and Exchange Commission. These forward-looking statements represent the views of the company as of the date of this release and should not be relied upon as representing the views of Kala as of any date subsequent to the date hereof. Kala undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor contacts:

Jill Steier jill.steier@kalarx.com 781-996-5252

Hannah Deresiewicz hannah.deresiewicz@sternir.com 212-362-1200

]]>